Drug Trial Radar · NCT07024277
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Conditions
- Neuroendocrine Prostate Cancer
Interventions
ZG006Biological
ZG006 will be administered as an intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Best Overall Response(mBOR)Time frame: Baseline to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan university shanghai cancer center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.